<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002721</url>
  </required_header>
  <id_info>
    <org_study_id>UNM-2394C</org_study_id>
    <secondary_id>CDR0000064574</secondary_id>
    <secondary_id>NCI-V96-0816</secondary_id>
    <nct_id>NCT00002721</nct_id>
  </id_info>
  <brief_title>Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>A PHASE I TRIAL OF ESTRAMUSTINE PHOSPHATE AND DOXORUBICIN IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in&#xD;
      treating patients with metastatic recurrent prostate cancer that does not respond to hormone&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Estimate the maximum tolerated dose of weekly intravenous doxorubicin (DOX)&#xD;
      that can be given in combination with oral estramustine (EM) in patients with metastatic&#xD;
      prostate cancer refractory to treatment with hormonal agents. II. Assess the frequency of&#xD;
      expression of the multidrug resistance phenotype in biopsy specimens from these patients.&#xD;
      III. Assess the response to DOX/EM in these patients.&#xD;
&#xD;
      OUTLINE: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Estramustine, EM,&#xD;
      NSC-89199.&#xD;
&#xD;
      PROJECTED ACCRUAL: Three to 18 patients will be entered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1995</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respond to therapy</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate cancer patients that have not responded to hormon therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Prostate cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
    <arm_group_label>Prostate cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>drug resistance inhibition treatment</intervention_name>
    <arm_group_label>Prostate cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Biopsy proven metastatic prostate cancer Biopsy requirement waived&#xD;
        at principal investigator's discretion if new disease site technically inaccessible and PSA&#xD;
        elevated Recurrent disease following orchiectomy, estrogen, or gonadotropin-releasing&#xD;
        hormone agonist therapy If previously irradiated: Progressive disease outside prior&#xD;
        radiotherapy field required No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:&#xD;
        Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL ALT/AST less than 3 times&#xD;
        greater than normal Renal: Not specified Cardiovascular: Left ventricular ejection fraction&#xD;
        at least 45% No NYHA class III/IV status No unstable angina Other: No Crohn's disease,&#xD;
        ulcerative colitis, or other inflammatory bowel syndrome&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        doxorubicin or estramustine Endocrine therapy: See Disease Characteristics At least 30 days&#xD;
        since flutamide Estrogen or gonadotropin-releasing hormone agonists discontinued prior to&#xD;
        treatment Radiotherapy: At least 6 weeks since radiotherapy Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Y. Smith, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research &amp; Treatment Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2004</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

